Related Experiment Video
Updated: Sep 18, 2025

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Correction to "Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell
Abstract:
Oluwole OO, Bouabdallah K, Muñoz J, De Guibert S, Vose JM, Bartlett NL, et al. Br J Haematol. 2021;194(4):690-700. On page 3 of the "Bridging Therapy Regimens" section of the Supplementary Appendix methods, the dose of rituximab that was administered in combination with bendamastine as optional bridging therapy was incorrectly reported as 275 mg/m2. The proper dose of rituximab was 375 mg/m2, and the text should have read: "Bendamustine (90 mg/m2 on days 1 and 2) in combination with rituximab (375 mg/m2 on day 1)." We apologize for this error.
More Related Videos
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Drugs for Treatment of Ulcerative Colitis in IBD
COPD: Management Using Bronchodilators and Corticosteroids